Table 1.
Romanian experience with the use of blinatumomab for B-cell ALL until May 2019.
| Case number | Sex | Age | Phenotype | CRS | SCT | Treatment protocol | MRD after first line | OS months | OS censor | RFS months | RFS censor | Fusion protein | Cytogenetics |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 24 | Common ALL | NA | MUD | Hyper CVAD | Positive | 68 | 0 | 44 | 1 | NA | NA |
| 2 | M | 49 | Pro B-ALL | CRS | Haplo | EORTC | Positive | NA | NA | NA | NA | NA | NA |
| 3 | F | 39 | B-ALL | NA | NA | GRAALL | Negative | 1 | 1 | 1 | 0 | BCR-ABL1 | NA |
| 4 | M | 18 | B-ALL | CRS | NA | BFMALL200 | Negative | 39 | 0 | 32 | 1 | E2A-PBX1 | Normal karyotype |
| 5 | M | 25 | Common ALL | NA | NA | PETHEMAALL93 | Negative | 20 | 0 | 5 | 1 | NA | del 6q21 |
| 6 | F | 42 | Pro B-ALL | NA | MUD | PETHEMAALL93 | Positive | 29 | 0 | 2 | 1 | MLL-AF4 | Hyperdiploid karyotype |
| 7 | F | 48 | Common ALL | NA | NA | PETHEMAALL93 | Positive | 15 | 0 | 15 | 0 | NA | Aneuploidy |
| 8 | F | 33 | Pro B-ALL | NA | NA | PETHEMAALL93 | Negative | 59 | 0 | 54 | 1 | MLL-AF4 | del TP53 |